COVID-19 Records

Additional OSP comments: TA on Risky Research Review Act

Reading Room Production, pp.123-124 · reading_room:email:00126

Page text: p.123, p.124 · original PDF

Date
2024-07-15 12:26
Type
email · email
cc
Emily Erbelding, Steven Holland, Christopher Hanson, Kelly Poe, Sharon Gilles, Ddsm Correspondences
sender
Sara Selgrade
to
Robert Eiss, Michael Nealy, Hugh Auchincloss, Jill Harper, Marie Parker, Courtney Billet

This text appears inside a quoted reply chain — it is evidence that the message was circulating, not necessarily a new message.

This is a duplicate copy. Canonical version: reading_room:email:00143

ol ol a 5 AM [AID DEA DART NIAID) [E] 7 NIAID) [E] \IH/NIAID) [E] ii NIH/NIAID) [E] J VIH/NIAID) [I] iy >; I I (NIH/NIAID) [E] NIH/NIAID) [E] ay NIAID) [E] In the attached revised draft, I jections, I will submit these to NIH tt iy PM [AID DEA DART NIAID) (E] i I NIAID) [E] \IH/NIAID) [E] ii NIH/NIAID) [E] J VIH/NIAID) [Ee] >; I I (NIH/NIAID) [E] NIH/NIAID) [E] ay NIAID) [E] Hello all, For your awareness, we are providing the attached comments on the Risky Research Review Act from the NIH Office of Science Policy (OSP). We anticipate receiving consolidated NIH comments on the bill, and we will share these as soon as we have them. Please let me know if you have any questions. Thanks, Sara

In context

A single line often inverts meaning once you see what it answers, so neighbouring messages are always shown.

  1. 2024-07-15 12:26 Sara Selgrade open
    Hello all, For your awareness, we are providing the attached comments on the Risky Research Review Act from the NIH Office of Science Policy (OSP). We anticipate receiving consolidated NIH comments on the bill, and we will share these as soon as we have them. Please let me know if you have any questions. Thanks, Sara
  2. 2024-07-15 12:26 Sara Selgrade
    ol ol a 5 AM [AID DEA DART NIAID) [E] 7 NIAID) [E] \IH/NIAID) [E] ii NIH/NIAID) [E] J VIH/NIAID) [I] iy >; I I (NIH/NIAID) [E] NIH/NIAID) [E] ay NIAID) [E] In the attached revised draft, I jections, I will submit these to NIH tt iy PM [AID DEA DART NIAID) (E] i I NIAID) [E] \IH/NIAID) [E] ii NIH/NIAID) [E] J VIH/NIAID) [Ee] >; I I (NIH/NIAID) [E] NIH/NIAID) [E] ay NIAID) [E] Hello all, For your awareness, we are providing the attached comments on the Risky Research Review Act from the NIH Office of Science Policy (OSP). We anticipate receiving consolidated NIH comments on the bill, and we will share these as soon as we have them. Please let me know if you have any questions. Thanks, Sara
  3. 2024-07-15 12:26 Sara Selgrade open
    Hello all, For your awareness, we are providing the attached comments on the Risky Research Review Act from the NIH Office of Science Policy (OSP). We anticipate receiving consolidated NIH comments on the bill, and we will share these as soon as we have them. ol ol a 5 AM AID DEA DART NIAID) [E] 7 NIAID) [E] \IH/NIAID) [E] ii a NIH/NIAID) [E] VIH/NIAID) [E] iy >; || (NIH/NIAID) [E] NIH/NIAID) [E] ay NIAID) [E] In the attached revised draft, I jections, I will submit these to NIH D) (e)] PM [AID DEA DART NIAID) (E] i I \IH/NIAID) [E] ii a NIH/NIAID) [E] NIAID) [E] VIH/NIAID) [E] iy >; I I (NIH/NIAID) [E] NIH/NIAID) [E] ay NIAID) [E] has asked us to Please let me know if you have any questions. Thanks, Sara
  4. 2024-07-15 12:26 Sara Selgrade open
    Hello all, For your awareness, we are providing the attached comments on the Risky Research Review Act from the NIH Office of Science Policy (OSP). We anticipate receiving consolidated NIH comments on the bill, and we will share these as soon as we have them. Please let me know if you have any questions. Thanks, ol ol a 5 AM AID DEA DART NIAID) [E] 7 NIAID) [E] \IH/NIAID) [E] ii NIH/NIAID) [E] J VIH/NIAID) [I] iy >; I I (NIH/NIAID) [E] NIH/NIAID) [E] ay NIAID) [E] In the attached revised draft, I jections, I will submit these to NIH tt iy PM [AID DEA DART NIAID) (E] i I NIAID) [E] \IH/NIAID) [E] ii NIH/NIAID) [E] J VIH/NIAID) [Ee] >; I I (NIH/NIAID) [E] NIH/NIAID) [E] ay NIAID) [E] has asked us to ze Sara
  5. 2024-07-15 12:26 Sara Selgrade open
    Hello all, For your awareness, we are providing the attached comments on the Risky Research Review Act from the NIH Office of Science Policy (OSP). We anticipate receiving consolidated NIH comments on the bill, and we will share these as soon as we have them. Please let me know if you have any questions. Thanks, Sara

Full conversation →